NASDAQ:REVB Revelation Biosciences (REVB) Stock Price, News & Analysis → Gold Set to EXPLODE! (From Gold Safe Exchange) (Ad) Free REVB Stock Alerts $2.06 -0.14 (-6.36%) (As of 05/10/2024 ET) Add Compare Share Share Today's Range$2.01▼$2.2350-Day Range$1.83▼$3.6452-Week Range$1.78▼$39.00Volume38,244 shsAverage Volume284,048 shsMarket Capitalization$3.36 millionP/E Ratio0.07Dividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Revelation Biosciences alerts: Email Address Revelation Biosciences MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy1.09% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($20.32) to ($18.88) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.84 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Revelation Biosciences.Read more about Revelation Biosciences' stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted1.09% of the float of Revelation Biosciences has been sold short.Short Interest Ratio / Days to CoverRevelation Biosciences has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Revelation Biosciences has recently decreased by 4.32%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldRevelation Biosciences does not currently pay a dividend.Dividend GrowthRevelation Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for REVB. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for Revelation Biosciences this week, compared to 0 articles on an average week.MarketBeat Follows4 people have added Revelation Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Revelation Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.22% of the stock of Revelation Biosciences is held by insiders.Percentage Held by InstitutionsOnly 12.80% of the stock of Revelation Biosciences is held by institutions.Read more about Revelation Biosciences' insider trading history. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Revelation Biosciences are expected to grow in the coming year, from ($20.32) to ($18.88) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Revelation Biosciences is 0.07, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 143.69.Price to Earnings Ratio vs. SectorThe P/E ratio of Revelation Biosciences is 0.07, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 176.29.Price to Book Value per Share RatioRevelation Biosciences has a P/B Ratio of 0.08. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Revelation Biosciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaElon Musk Secret Crypto Plot ExposedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. About Revelation Biosciences Stock (NASDAQ:REVB)Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-100, a potential therapy for the prevention and treatment of healthcare-associated bacterial infection resulting from surgery, severe burns, urinary tract infection, sepsis, and antibiotic resistance; REVTx-200, a potential intranasal therapy; and REVTx-300, a potential therapy for the treatment of chronic organ disease, including chronic kidney disease. It is also developing REVTx-99b, a treatment for food allergies; REVTx-99a, an anti-viral nasal drop solution for the potential prevention or treatment of respiratory viral infection; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, influenza A, influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.Read More REVB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart REVB Stock News HeadlinesMay 10, 2024 | businesswire.comRevelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024March 22, 2024 | businesswire.comRevelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023May 10, 2024 | Crypto 101 Media (Ad)Tech GIANT’s Plans to Revolutionize Crypto…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. March 13, 2024 | finance.yahoo.comRevelation Biosciences Inc. Gives Oral Presentation at Advances in Critical Care Nephrology (AKI & CRRT 2024)March 4, 2024 | finance.yahoo.comRevelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of GeminiFebruary 13, 2024 | finance.yahoo.comRevelation Biosciences Inc. Receives Invitation to Give an Oral Presentation at The 29th International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)February 9, 2024 | msn.comRevelation Biosciences Secures $6.2M in Public OfferingFebruary 5, 2024 | finance.yahoo.comRevelation Biosciences Inc. Announces Closing of $6.2 Million Public OfferingMay 10, 2024 | Crypto 101 Media (Ad)Tech GIANT’s Plans to Revolutionize Crypto…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. February 2, 2024 | marketwatch.comRevelation Biosciences Shares Slide Premarket on Public OfferingFebruary 1, 2024 | msn.comRevelation Biosciences to raise ~$6.2M through public offering of sharesFebruary 1, 2024 | investorplace.comWhy Is Revelation Biosciences (REVB) Stock Down 62% Today?January 30, 2024 | finance.yahoo.comRevelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)January 29, 2024 | seekingalpha.comFATE, NEXI and INBS among mid-day moversJanuary 26, 2024 | finance.yahoo.comREVB Continues March to TrialsJanuary 23, 2024 | finance.yahoo.comRevelation Biosciences Inc. Announces 1-for-30 Reverse Stock Split Effective January 25, 2024November 22, 2023 | morningstar.comRevelation Biosciences Inc Ordinary Shares REVBNovember 14, 2023 | finance.yahoo.comREVB Releases Earnings and Prepares for TrialsNovember 14, 2023 | msn.comRevelation Biosciences GAAP EPS of -$0.42November 13, 2023 | finance.yahoo.comRevelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2023October 12, 2023 | finance.yahoo.comGemini Induces Pharmacologic Activity and Related Physiologic Changes in Multiple Preclinical StudiesOctober 4, 2023 | finance.yahoo.comRevelation Biosciences, Inc. to Present at the 2023 ROTH Healthcare Opportunities ConferenceOctober 2, 2023 | finance.yahoo.comRevelation Biosciences Inc. Announces Appointment of Lakhmir Chawla, M.D. to Board of DirectorsAugust 14, 2023 | finance.yahoo.comREVB Reports Solid Balance Sheet and Remains on TrackAugust 11, 2023 | finance.yahoo.comRevelation Biosciences Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2023June 29, 2023 | finance.yahoo.comREMINDER: Revelation Biosciences, Inc. Urges All Stockholders to Vote at the 2023 Annual Meeting of StockholdersJune 22, 2023 | finance.yahoo.comREVB: REVB Looks Attractive Ahead of TrialsSee More Headlines Receive REVB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Revelation Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/22/2024Today5/10/2024Next Earnings (Estimated)5/27/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:REVB CUSIPN/A CIK1810560 Webwww.revbiosciences.com Phone650-800-3717FaxN/AEmployees9Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$30.41 Trailing P/E Ratio0.07 Forward P/E RatioN/A P/E GrowthN/ANet Income$-120,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-84.25% Return on Assets-51.31% Debt Debt-to-Equity RatioN/A Current Ratio2.18 Quick Ratio2.18 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$25.13 per share Price / Book0.08Miscellaneous Outstanding Shares1,633,000Free Float1,629,000Market Cap$3.36 million OptionableNot Optionable Beta0.17 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. James M. Rolke (Age 55)CEO & Director Comp: $649.25kMr. Chester Stanley Zygmont III (Age 44)CFO & Corporate Secretary Comp: $479.14kMs. Sandra VedrickVice President of Human Resources & Investor RelationsMs. Carol OdleSenior Director of Clinical ProjectsKey CompetitorsGeoVax LabsNASDAQ:GOVXEvoke PharmaNASDAQ:EVOKPhio PharmaceuticalsNASDAQ:PHIOAtrecaNASDAQ:BCELEnsysce BiosciencesNASDAQ:ENSCView All CompetitorsInsidersGeorge F. TidmarshSold 925 sharesTotal: $14,430.00 ($15.60/share)George F TidmarshSold 365 sharesTotal: $7,227.00 ($19.80/share)George F TidmarshSold 47 sharesTotal: $972.90 ($20.70/share)George F TidmarshSold 133 sharesTotal: $2,952.60 ($22.20/share)George F TidmarshSold 400 sharesTotal: $9,000.00 ($22.50/share)View All Insider Transactions REVB Stock Analysis - Frequently Asked Questions How have REVB shares performed in 2024? Revelation Biosciences' stock was trading at $15.0210 at the beginning of 2024. Since then, REVB stock has decreased by 86.3% and is now trading at $2.06. View the best growth stocks for 2024 here. When is Revelation Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 27th 2024. View our REVB earnings forecast. How were Revelation Biosciences' earnings last quarter? Revelation Biosciences, Inc. (NASDAQ:REVB) posted its earnings results on Friday, March, 22nd. The company reported ($8.33) EPS for the quarter, topping analysts' consensus estimates of ($10.94) by $2.61. When did Revelation Biosciences' stock split? Revelation Biosciences's stock reverse split on Thursday, January 25th 2024. The 1-30 reverse split was announced on Thursday, January 25th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 25th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. How do I buy shares of Revelation Biosciences? Shares of REVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:REVB) was last updated on 5/10/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaGold Set to EXPLODE!Gold Safe ExchangeCharles Payne Demystifies OptionsUnstoppable ProsperityHe Is Giving Away BitcoinCrypto Swap ProfitsMissed NVDA? Buy this AI stock NOWChaikin AnalyticsYou need to know these two things about AI stocks ASAP…InvestorPlaceShocking: One AI startup's revenue could surge 4,735%Manward Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revelation Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
